Question

I am a breastfeeding mother and i want to know if it is safe to use UNII-2P471X1Z11? Is UNII-2P471X1Z11 safe for nursing mother and child? Does UNII-2P471X1Z11 extracts into breast milk? Does UNII-2P471X1Z11 has any long term or short term side effects on infants? Can UNII-2P471X1Z11 influence milk supply or can UNII-2P471X1Z11 decrease milk supply in lactating mothers?

UNII-2P471X1Z11 lactation summary

UNII-2P471X1Z11 usage has low risk in breastfeeding
  • DrLact safety Score for UNII-2P471X1Z11 is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of UNII-2P471X1Z11 may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that UNII-2P471X1Z11 may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of UNII-2P471X1Z11 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using UNII-2P471X1Z11 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About UNII-2P471X1Z11 usage in lactation

Monoclonal antibody against immunoglobulin E (IgE).It is an immunoglobulin G (IgG) of huge molecular weight that binds with great affinity to IgE, blocking it, forming IgG-IgE complexes of even larger size and molecular weight. Since the last update, we have not found published data on its excretion in breast milk. Its high molecular weight makes its excretion in milk very unlikely. Its low oral bioavailability would hinder its transfer to infant plasma from ingested breast milk since, due to its protein nature, it degrades in the gastrointestinal tract, and is not absorbed, except in premature infants and the immediate neonatal period, when there may be greater intestinal permeability. It is known that in non-human primates (cynomolgus monkeys) it is excreted in very small amounts: levels of UNII-2P471X1Z11 in milk were 0.15% (EMA 2016) or 1.5% (Grunewald 2015, FDA 2007) with respect to maternal serum concentration. Its use is authorized in children from 6 years of age (EMA 2016, Pediamecum 2015). Other monoclonal antibodies of similar structure and molecular weight (adalimumab, certolizumab, infliximab) are known not to be excreted in breast milk in clinically significant amounts and do not harm the infant, and are therefore considered compatible with breastfeeding. See below the information of these related products:

Answer by DrLact: About UNII-2P471X1Z11 usage in lactation

No information is available on the clinical use of UNII-2P471X1Z11 during breastfeeding. Because UNII-2P471X1Z11 is a large protein molecule with a molecular weight of 145,058, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, UNII-2P471X1Z11 should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Alternate Drugs

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.